The relation of polymer structure of stent used in patients with acute coronary syndrome revascularized by stent implantation with long‐term cardiovascular events

Introduction Drug‐eluting stents (DES) have revolutionized percutaneous coronary intervention (PCI) by improving event‐free survival compared to older stent designs. However, early‐generation DES with polymer matrixes have raised concerns regarding late stent thrombosis due to delayed vascular healing. To address these issues, biologically bioabsorbable polymer drug‐eluting stents (BP‐DES) and polymer‐free drug‐eluting stents (PF‐DES) have been developed. Aim The aim of the present study is to evaluate and compare the long‐term effects of different stent platforms in patients with acute coronary syndrome (ACS) undergoing PCI. Material and Methods We conducted a retrospective, observational study involving 1192 ACS patients who underwent urgent PCI. Patients were treated with thin‐ strut DP‐DES, ultra‐thin strut BP‐DES, or thin‐strut PF‐DES. The primary endpoint was a composite of cardiac death, target vessel myocardial infarction (TVMI), and clinically driven target lesion revascularization (CITLR) at 12 months and 4 years. Results The baseline demographics and clinical characteristics of patients in the three stent subgroups were similar. No significant differences were observed in target lesion failure (TLF), cardiac mortality, TVMI, and stent thrombosis (ST) rates among the three subgroups at both 12 months and 4 years. However, beyond the first year, the rate of CITLR was significantly lower in the ultra‐thin strut BP‐DES subgroup compared to thin‐strut DP‐DES, suggesting potential long‐term advantages of ultra‐thin strut BP‐DES. Additionally, both ultra‐thin strut BP‐DES and thin‐strut PF‐DES demonstrated lower ST rates after the first year compared to thin‐strut DP‐DES. Conclusion Our study highlights the potential advantages of ultra‐thin strut BP‐DES in reducing CITLR rates in the long term, and both ultra‐thin strut BP‐DES and thin‐strut PF‐DES demonstrate lower rates of ST beyond the first year compared to thin‐strut DP‐DES. However, no significant differences were observed in overall TLF, cardiac mortality and TVMI rates among the three stent subgroups at both 12 months and 4 years.